ReviewGenes2021
Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis.
Review in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Histone and Histone Acetylation-Related Alterations of Gene Expression in Uninvolved Psoriatic Skin and Their Effects on Cell Proliferation, Differentiation, and Immune Responses.International journal of molecular sciences · 2023Pooled it
- Pooled it
- Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis-Real-World Evidence up to 64 Weeks of Therapy.Medical sciences (Basel, Switzerland) · 2026Article
- Impact of Obesity on the Long-Term Outcomes of Advanced Therapies in IBD: A Real-World Study in Taiwan.Journal of inflammation research · 2025Article
- Efficacy and Safety of Apremilast in Oncological Patients with Moderate-to-Severe Plaque Psoriasis: A 5 years Retrospective Observational Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends.Recent advances in inflammation & allergy drug discovery · 2025Review
- Article
- Functional Genomics in Psoriasis.International journal of molecular sciences · 2024Review
- Macrophage Functions in Psoriasis: Lessons from Mouse Models.International journal of molecular sciences · 2024Review
- Single-Cell Sequencing and Machine Learning Integration to Identify Candidate Biomarkers in Psoriasis:Journal of inflammation research · 2024Article
- A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review.International journal of molecular sciences · 2023Review
- Inflammation and Psoriasis: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Genetic and Epigenetic Mechanisms of Psoriasis.Genes · 2023Review
- Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis.Pharmaceutics · 2023Article
- Evidence on the therapeutic role of thiolutin in imiquimod-induced psoriasis-like skin inflammation in mice.Immunity, inflammation and disease · 2023Article
- Prevalence of Female Sexual Dysfunction Among Psoriatic Females: A Cross Sectional Case Controlled Study.Dermatology practical & conceptual · 2023Article
- Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus.Dermatology reports · 2023Article
- Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.International journal of molecular sciences · 2023Review
- Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomic studies allowed the reasons behind the different responses to treatments to be understood. Its clinical utility, in fact, is demonstrated by the reduction in adverse drug reaction incidence and the improvement of drug efficacy. Pharmacogenomics is an important tool that is able to improve the drug therapy of different disorders. In particular, this review will highlight the current pharmacogenomics knowledge about biologics and small-molecule treatments for psoriasis. To date, studies performed on genes involved in the metabolism of biological drugs (tumor necrosis factor inhibitors and cytokines inhibitors) and small molecules (apremilast, dimethyl fumarate, and tofacitinib) have provided conflicting results, and further investigations are necessary in order to establish a set of biomarkers to be introduced into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.